The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing ...

Novo Nordisk will hold a meeting to elect new board members following a disagreement between the board and its majority shareholder.

The results strengthen Jiangsu Hengrui’s dominance in the Chinese HCC market, showing potential for camrelizumab and ...

Ventus has entered a multi-year partnership with Roche’s Genentech for the discovery and optimisation of new small-molecule ...

Health Canada has granted conditional approval for Gilead Sciences’ Lyvdelzi for PBC patients who have difficulty with ...

Gibson, Dunn & Crutcher and White & Case have emerged as the foremost legal advisers for mergers and acquisitions (M&A) in ...

Morgan Stanley has secured the leading position as a financial adviser by deal value in South & Central America's M&A sector.

JP Morgan and Rothschild & Co have emerged as the top mergers and acquisitions (M&A) financial advisers in the Middle East & ...

In the realm of M&A, Skadden, Arps, Slate, Meagher & Flom, and Veirano Advogados have emerged as the top legal advisers in ...

Merck KGaA could now have a head start in the race to market Precem-TcT, which could become the first widely approved ADC in ...

The EU's Annex 1 regulations promote mutual recognition of inspections and regulatory cooperation while demanding rigorous compliance.

At AAO 2025, EyePoint Pharmaceuticals presented updates on its investigational therapy EYP-1901 (vorolanib) for DME and wAMD.